BUSINESS: Incubate Policy Laboratory And Charles River Associates Report Finds That Price Controls Could Decrease Investments In Critical Therapeutic Areas

dWeb.News Article from Daniel Webster dWeb.News

Daniel Webster, dWeb.News Publisher

Washington, D.C., Nov. 18, 2021 (GLOBE NEWSWIRE) — Today, Incubate Policy Lab and Charles River Associates published a report detailing how investment into therapies for rare diseases and oncology will plummet if Congress enacts price controls.

Despite the pleas of life-science investors, Congress is moving ahead with government-mandated medicines prices,” stated John Stanford, Incubate executive director. “Our report clearly shows that price controls will allow those who finance the development of cutting-edge medicines to steer their money towards safer investment opportunities. “

The report was based on interviews with people working in the pharmaceutical industry as well as early-stage investors in life sciences. Participants agreed that price controls would force investment dollars away form therapeutic areas that have been particularly risky, such as cell and gene therapy, Alzheimer’s, and rare diseases, in favor of areas with lower development costs, more predictable returns, and less risk.

They also agreed that the negative effect of reference pricing, both domestic and international, would cause pharmaceutical companies to delay or stop launching new drugs in the United States. It would also reduce patient access and investment in transformative innovations.

“Researchers are developing new and urgently needed treatments for Alzheimer’s disease, ALS, HIV and other rare diseases,” stated Stanford. I urge policymakers listen to the people who fund this research and to reconsider their plans to introduce price controls. “

About Incubate Policy Lab: Incubate is a 501(c)(4) organization representing the patient, corporate, and investment communities whose aim is to educate policymakers on the role of venture in bringing promising ideas to patients in need. Incubate Policy Lab is the advocacy group’s research arm. It examines policy initiatives and their potential impacts on the biopharmaceutical sector.

About Charles River Associates. Charles River Associates, a global consulting firm that specializes in management, economic, and financial consulting services, is the leading global consultancy firm. CRA provides advice to clients in economic and financial matters relating to regulatory proceedings and litigation. It also guides corporations on critical business strategies and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. CRA is headquartered in Boston and has offices around the globe. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at www.crai.com. Follow us on LinkedIn, Twitter, and Facebook.

For more dWeb.News Business News: https://dweb.news/news-sections/business-news/

The post BUSINESS: Incubate Policy Laboratory And Charles River Associates Report Finds That Price Controls Could Decrease Investments In Critical Therapeutic Areas appeared first on dWeb.News dWeb.News from Daniel Webster Publisher dWeb.News – dWeb Local Tech News and Business News

dWeb.NewsRead More

Similar Posts